Search Results

You are looking at 21 - 30 of 221 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018

Weijia Wang, Edward Li, Kim Campbell, and Ali McBride

prophylaxis date. FN was defined using claims with a diagnosis code for neutropenia (main definition), neutropenia with fever or infection (sensitive definition) and neutropenia with fever (specific definition). FN incidence among the first chemotherapy cycle

Full access

BPI20-015: Safety and Financial Analysis of Outpatient Dose-Adjusted EPOCH for B-cell Lymphoma at a Tertiary Comprehensive Cancer Center

Wenhui Li, Katherine Simondsen, Katherine Tobon, Kevin McCarthy, and Timothy Kubal

incidence of neutropenic fever, extravasations, drug spills, pump-malfunctions, and drug-related adverse events. Financial data was conducted through the institution’s financial department. Results: 88% (193 of 219) of DA-EPOCH cycles were administered

Full access

NCCN Guidelines® Updates: Management of Immunotherapy-Related Toxicities

-cell transplant experience. Close monitoring in the hospital...” ➤ 2nd bullet was revised: “Hospitalization is warranted for patients with at the first sign of CRS or neurotoxicity (including fever, hypotension, or change in mental status) is warranted

Full access

YIA23-003: CD19-CAR T Cells Develop Exhaustion Epigenetic Programs During a Clinical Response

Caitlin Zebley, Charmaine C Brown, Tian Mi, Yiping Fan, Shanta Alli, Shannon Boi, Giovanni Galletti, Enrico Lugli, Deanna Langfitt, Jean-Yves Metais, Timothy Lockey, Michael Meagher, Brandon Triplett, Aimee Talleur, Stephen Gottschalk, and Ben Youngblood

by cross-referencing our epigenetic data with publicly available transcriptional profiles for antigen-specific effector and long-lived memory CD8 T cells from individuals vaccinated for yellow fever. Furthermore, we show that CAR T cells were unable

Full access

Timing of Initial Antibiotic Treatment for Febrile Neutropenia in the Emergency Department: The Need for Evidence-Based Guidelines

Demetrios N. Kyriacou, Borko Jovanovic, and Olga Frankfurt

suppression with resultant leukopenia that renders these patients susceptible to serious infections, often with fever as the only clinical finding. 5 – 8 This complication, known as febrile neutropeni a (FN), occurs in 10% to 30% of patients undergoing

Full access

Mimicking MacGyver in the Oncology Clinic: Improvisation and Creative Solutions, Only Rarely Involving Duct Tape

David P. Steensma

low-grade fever during the night, and the PICC team’s policy is that all cultures must be negative for 48 hours before a line can be placed. (This scenario is not difficult for me to visualize, since it happened to me twice recently.) You might wait 48

Full access

Counterpoint: Hyperthermia with Radiation Therapy for Chest Wall Recurrences

Beryl McCormick

: Perez CA, Brady LW, eds. Principles and Practices of Radiation Oncology . Philadelphia : J B Lippincott ; 1987 : 317 – 352 . 2. Warren S . Preliminary study of the effect of artificial fever upon hopeless tumor cases . Am J Roentgenol

Full access

CLO23-060: Extranodal Presentation of Double Hit High Grade B Cell Lymphoma

Ernesto Munoz and Allison Carilli

. Our patient has a rearrangement of the MYC and BCL-6 oncogenes which is the least common and is considered to have a worse prognosis. HGBL commonly presents with extranodal disease, lymphadenopathy, fever, night sweats, weight loss, loss of appetite

Full access

CLO22-081: Clinical Efficacy and Quality of Life of Oral Cancer Patients Treated With Paclitaxel/Cisplatin/5-FU Vs Paclitaxel/Carboplatin Chemotherapeutic Regimens in a Tertiary Cancer Center in Eastern India

Pranab Kumar Sahoo, Sinjini Sarkar, Sutapa Mahata, Ranita Pal, Tanuma Mistry, Sushmita Ghosh, Trisha Choudhury, Sriparna Datta, Anup Kumar Bhowmick, Kalyan Kusum Mukherjee, and Vilas D Nasare

toxicities like anaemia (13.3%) followed by neutropenia (2.4%) and thrombocytopenia (2.4%) whereas non-hematological toxicities include diarrhoea (30.5%), vomiting (26.6%), fever (23.1%), myalgia (19.7%) and mucositis (5.41%). 82 (40.39%) patients succumbed

Full access

HSR22-154: Treatment Patterns Following Osimertinib Discontinuation in Patients With EGFR Mutated Metastatic NSCLC

Elizabeth Marrett, Winghan Jacqueline Kwong, Jinlin Song, Ameur M. Manceur, Selvam Sendhil, and Eric Wu

/pneumonitis (3.0), infection/sepsis (2.1), nausea and vomiting (1.9), fever (1.7), and diarrhea (1.5). Conclusions : After osimertinib discontinuation, plat-chemo regimens were the most common subsequent LOT, followed by reuse of EGFR-TKIs. Overall, the